Agios Pharma (AGIO) AI Stock Analysis

• Market Cap: $2.30B
• Dividend Yield: N/A
• Average Volume (3M): 626.81K
• Price to Earnings (P/E): 3.5
• Beta (1Y): 1.67
• Revenue Growth: 25.96%
• EPS Growth: N/A
• Country: US
• Employees: 486
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -1.55
• Shares Outstanding: 57,915,200
• 10 Day Avg. Volume: 754,917
• 30 Day Avg. Volume: 626,812
• PEG Ratio: -3.97
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.59
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 16.29
• Enterprise Value/Gross Profit: 72.80
• Enterprise Value/Ebitda: -1.35
• 1Y Price Target: $57.00
• Price Target Upside: 42.50% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 67 Neutral
• Price Target: $42.00 ▲(5.00%Upside)

Agios Pharma's overall score reflects strong technical indicators and positive corporate events, counterbalanced by financial performance challenges and an uncertain revenue outlook. The company's strategic initiatives and potential product launches provide a growth opportunity, but operational efficiency improvements are critical.

Positive Factors

Clinical Trials

Mitapivat's Phase 2 data has shown encouraging efficacy in sickle cell disease, indicating potential success in future trials and approvals.

Partnerships

Agios Pharmaceuticals has established a commercial and distribution partnership with Avanzanite for Pyrukynd in Europe, Switzerland, and the United Kingdom, which is viewed favorably as it aligns with their strategic focus.

Regulatory Progress

The regulatory process for mitapivat is progressing ex-US, including in the Gulf Cooperation Council region, which represents a significant opportunity in thalassemia.

Negative Factors

Revenue and Financial Performance

The company reported $8.7 million in 1Q25 revenues for mitapivat, missing consensus estimates of $10.1 million.

Revenue Share Agreement

Analyst's price target for Agios has been lowered due to the expectation of a revenue share agreement with Avanzanite, which initially favors Avanzanite in terms of revenue distribution.

Safety Concerns

Concerns over hepatocellular injury have negatively impacted AGIO stock, which is down approximately 45% due to these issues observed in thalassemia patients.

Agios Pharma Business Overview & Revenue Model

Company Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Agios Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary therapeutic products. The company's revenue streams include product sales, collaborations, and licensing agreements. Agios has partnered with various pharmaceutical companies to co-develop and commercialize its products, which provides milestone payments and royalties as a significant source of income. Additionally, the company may receive research funding and grants to support its drug discovery and development efforts. By advancing its pipeline of potential therapies through clinical trials and achieving regulatory approvals, Agios aims to expand its market presence and increase its revenue from product sales.

Agios Pharma Financial Statement Overview

Summary

Agios Pharma's financial performance is challenged by inconsistent revenue trends and significant operational losses. While the company has a strong equity position, it struggles with negative cash flow and profitability, which impacts its financial health.

Income Statement

Agios Pharma has shown inconsistent revenue trends with a significant decline from $203.2M in 2020 to $36.5M in 2024. Despite this, the TTM data shows a slight revenue increase compared to 2024. Gross profit margins have been generally high, but EBIT and EBITDA margins are negative due to substantial operating losses, indicating challenges in achieving operational profitability. The net profit margin is skewed by a significant net income figure in some periods due to non-operational factors.

Balance Sheet

The company maintains a strong equity position with low leverage, evidenced by the debt-to-equity ratio and high equity ratio. Stockholders' equity consistently exceeds total liabilities, showcasing financial stability. However, the company needs to manage its debt levels prudently given the negative EBIT and EBITDA, which could stress financial health if cash reserves diminish.

Cash Flow

Agios Pharma's cash flow statements reveal negative operating and free cash flows, indicating the company is not generating cash from its operations. While investing cash flow is positive, largely due to asset sales, the reliance on such activities is unsustainable long-term. The company must improve operational cash generation to ensure financial resilience.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.50M	26.82M	14.24M	0.00	203.20M
Gross Profit	32.33M	17.32M	12.54M	-18.78M	200.39M
EBITDA	-425.74M	-384.86M	-380.48M	-337.73M	-326.13M
Net Income	673.73M	-352.09M	-74.56M	1.60B	-335.22M
Balance Sheet
Total Assets	1.66B	937.12M	1.24B	1.44B	852.95M
Cash, Cash Equivalents and Short-Term Investments	893.71M	776.93M	1.10B	1.29B	670.54M
Total Debt	56.99M	72.00M	85.66M	97.09M	105.20M
Total Liabilities	122.24M	126.10M	137.90M	145.76M	453.45M
Stockholders Equity	1.54B	811.02M	1.10B	1.29B	399.50M
Cash Flow
Free Cash Flow	-391.53M	-297.06M	-314.36M	-413.06M	-305.67M
Operating Cash Flow	-389.84M	-296.06M	-309.48M	-407.32M	-290.76M
Investing Cash Flow	363.44M	239.57M	243.26M	1.25B	75.75M
Financing Cash Flow	14.44M	5.43M	2.35M	-765.77M	261.52M

Agios Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 40.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGIO, the sentiment is Positive. The current price of 40 is above the 20-day moving average (MA) of 38.01, above the 50-day MA of 34.66, and above the 200-day MA of 37.02, indicating a bullish trend. The MACD of 1.69 indicates Positive momentum. The RSI at 65.57 is Neutral, neither overbought nor oversold. The STOCH value of 49.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AGIO.

Agios Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AGIO	67 Neutral	$2.30B	3.51	60.26%	―	25.96%	―
NAMS	62 Neutral	$2.63B	―	-31.51%	―	―	―
RXRX	61 Neutral	$2.71B	―	-86.10%	―	29.32%	-11.00%
Sector *	52 Neutral	$7.60B	0.11	-62.95%	2.07%	16.16%	0.31%
IBRX	52 Neutral	$2.66B	―	78.99%	―	10238.41%	47.67%
APGE	49 Neutral	$2.48B	―	-27.85%	―	―	-94.92%
DNLI	45 Neutral	$2.08B	―	-35.21%	―	-100.00%	-144.79%

Agios Pharma Corporate Events

Agios Pharma Appoints Dr. Jay Backstrom as Director

On July 3, 2025, Agios Pharmaceuticals announced the election of Dr. Jay Backstrom as a class III director, effective July 8, 2025, with a term lasting until the 2028 Annual Meeting of Stockholders. Dr. Backstrom will also join the Science and Technology Committee and receive compensation in line with the company’s non-employee director policy, including cash compensation and stock options. This strategic addition to the board is expected to enhance Agios’s focus on scientific and technological advancements, potentially impacting its market positioning and stakeholder relations positively.

The most recent analyst rating on (AGIO) stock is a Hold with a $56.00 price target. To see the full list of analyst forecasts on Agios Pharma stock, see the AGIO Stock Forecast page.

Agios Pharma Increases Shares in Stock Incentive Plan

At the 2025 Annual Meeting of Stockholders held on June 18, Agios Pharmaceuticals’ stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing the number of shares available for issuance by 2,500,000. Additionally, the stockholders elected two directors, approved executive compensation, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year, reflecting strong support for the company’s strategic direction.

The most recent analyst rating on (AGIO) stock is a Hold with a $56.00 price target. To see the full list of analyst forecasts on Agios Pharma stock, see the AGIO Stock Forecast page.